New combo shrinks hard-to-treat breast tumors before surgery
NCT ID NCT02689427
First seen May 13, 2026 · Last updated May 13, 2026
Summary
This study tested a combination of enzalutamide (a hormone blocker) and paclitaxel (chemotherapy) given before surgery to people with a specific type of triple-negative breast cancer that has androgen receptors. The goal was to see if this treatment could shrink tumors and reduce the amount of tissue that needs to be removed. 24 adults with stage I-III breast cancer took part. The approach aims to control the disease and improve surgical outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
MD Anderson West Houston
Houston, Texas, 77079, United States
Conditions
Explore the condition pages connected to this study.